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Summary Survival (5- and 10-year) and prognostic factors of all differentiated thyroid cancer patients
(n= 1,055) occurring in Norway in 1970-79 are presented. The multivariate analysis (GLIM) revealed that
stage and age were the only significant prognostic factors. Sex and histological type could not be proved to be
of major prognostic value. The decline in relative survival with age was different in the three stages, appearing
as a continuous decrease in stage 3, while in stage 1 the decrease was present only in patients older than 75
years.
The Norwegian Thyroid Cancer Project was started in 1985.
An important purpose was the study of aetiological factors,
based on contrasts between incidence rates in different
geographical regions in Norway (Thoresen et al., 1986).
Furthermore, analysis of thyroglobulin and selenium in
premorbid serum-samples (The Janus Project) have recently
been published (Thoresen et al., 1988; Glattre et al., 1988)
and such results may also give clues to aetiology. The
present study was undertaken to clarify the prognostic
aspects of thyroid carcinoma in a representative and large
study population, especially with respect to clinicopatho-
logical data.
Thyroid carcinomas are rather heterogeneous, ranging
from anaplastic tumours, which kill most of the patients
within one year, to well differentiated follicular and papillary
types, with indolent behaviour and most often excellent
prognosis. It has been known for a long time that certain
clinical parameters and histopathological findings are of
prognostic significance. In 1979 EORTC proposed a concept
of risk groups in thyroid cancer (Byar et al., 1979), based on
sex, age, histology, T-category and distant metastases. Later,
several groups have used multifactorial analysis to determine
the individual contribution of such factors to the observed
survival rates. However, a major problem has been the
selection of patients for study, especially by time and place
of treatment. Heterogeneity in histological judgement may
also be present (Saxen et al., 1978). The studies undertaken
so far include small numbers of patients (Tennvall et al.,
1985) or, in larger series, cases have been collected for up to
30 years and from several different hospitals and regions
(Simpson et al., 1987).
In the present report on 1,055 patients with differentiated
thyroid cancer, all histological verified cases occurring in
Norway in 1970-79 were included. This was made possible
due to the Cancer Registry of Norway, which has almost
complete information on incidence and excellent follow-up
procedures. Thus, the main prognostic factors found by
others have been re-evaluated in the Norwegian population
using multivariate analysis and given an estimate for predic-
tive significance.
Materials and methods
The Cancer Registry of Norway has received detailed infor-
mation on nearly all cancer patients in Norway since 1953
(Cancer Registry of Norway, 1975). This includes clinical
data, histology and autopsy reports. Follow-up data on
recurrences are regularly filed, and the time and cause of
death are supplied once a year by the Central Bureau of
Statistics. The histopathological service in Norway has been
concentrated on a few university hospitals, and the health
service in general is rather uniform in all parts of the
country. About half of the patients were treated at The
Norwegian Radium Hospital and a uniform method of
assessment of lymph node and extension to the soft tissue of
the neck was performed. The other half were mainly treated
at four university hospitals, with mostly the same procedure
for neck dissection.
In the 10-year period 1970-79 a total of 1,482 cases of
thyroid cancer were reported. Histological examination had
been carried out in 1,422 of these cases (96%), while the
others were diagnosed clinically. Cases where thyroid cancer
was diagnosed at autopsy were excluded (n=228). Codings
of histological diagnoses were examined, and those not
fitting the 1974 WHO classification were reviewed on the
basis of histological reports and recoded when possible. This
study was confined to all 1,055 (88%) cases of papillary and
follicular carcinomas. The staging includes tumours localised
within the thyroid gland (stage 1), tumours with either
regional lymph node metastasis or direct extension to the
soft tissues of the neck (stage 2) and tumours with proven
distant metastasis at time of primary diagnosis (stage 3).
Staging was done post-surgically (histopathological).
Statistical methods
In our study we have used an analysis of relative survival
(Cancer Registry of Norway, 1982) with follow-up at 5 years
and 10 years when possible. The relative survival is defined
as the ratio of the observed survival rate in a group of
patients to the survival rate expected in a group similar to
the patients in such as age, sex and period, but free of the
specific disease under study. Information was collected up to
31 December 1986, giving a maximum follow-up of 17 years
after initial diagnosis. Patients with unknown staging were
excluded from the calculations of relative survival. Two
patients who emigrated during the follow-up period were
also excluded. The period of survival was reckoned from the
month of diagnosis, which was obtained from the hospital
reports. When only the year of diagnosis was known, this
month was set at July of that year.
A multivariate analysis of 5-year relative survival was also
performed using a generalised linear model as described by
Hakulinen and Tenkanen (1987). This model (GLIM) allows a
simultaneous analysis of the influence of several prognostic
factors on survival. Our analysis included sex (S), age (A: 0-
34, 35-54, 55-74 years), tumour stage (TS: stage 1, stage 2,
stage 3) and histological type (H: papillary, follicular).
Patients aged 75 years or above (n=97) were excluded from
the multivariate analysis because of unreliable estimates of
relative survival. To obtain as many patients as possible in
each category of the variables, only 5-year survival data were
used in this multivariate analysis.
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The results are expressed as estimates and standard devi-
ations (s.d.) of coefficients for categories of the variables
entered, showing contrasts in importance relative to reference
values of each variable. A positive value indicates a reduc-
tion in relative survival. The deviances, which measure
the fit between predicted and observed values of 5-year
relative survival, are compared to the deviance of a basic
model where all four variables are incorporated. Changes in
deviances and degrees of freedom are listed in separate
columns together with the corresponding P-value. The
deviances follow a x2 distribution. In turn, each of the four
variables has been removed from the explaining model to
test their importance for fitting the predictions with the
observed data. The resultant model, including only the
factors of significant importance, was used to estimate the
predicted values of 5-year relative survival.
Results
Distribution of sex, age, stage and histological type
Patients included in this survival study are listed in Tables I
and II. The overall sex ratio was 3.2:1, females showing the
higher figures. Table II shows that more than 60% of all
female cases were below 55 years, compared with 43% of the
males. Papillary carcinomas were most frequent (73%), the
rest being of the follicular type. The female:male ratio was
higher in follicular (5.1) than papillary tumours (2.8) and the
former were slightly younger. The majority of patients had
stage 1 tumours, 60% of papillary and 73% of follicular
carcinomas. About 5% of the papillary tumours had distant
metastases, compared with 11% of the follicular type. Figure
I shows that for both histological types the patients below
55 years have a more favourable clinical stage than elderly
cases, being most pronounced for the follicular type. Among
males with papillary tumours there was no difference.
Relative survival after 5 and 10 years
In Table III the 5- and 10-year relative survival (per cent)
for both histological types is summarised according to stage.
For both sexes patients with the papillary type had a
somewhat better overall prognosis than those with follicular
carcinomas, females showing the higher figures. In males,
there were no clear differences between papillary and follicu-
lar carcinomas in either stage 1 or stage 2, but follicular
tumours carried a worse prognosis in stage 3 in both sexes.
Additionally, there was a rather small difference in survival
rate for the papillary type with and without local metastases.
This difference is somewhat more apparent for follicular
tumours, especially among females. For both types the
decrease from 5-year to 10-year relative survival is rather
limited for stage I and stage 2 tumours. On the other hand,
patients with distant metastases apparently also died between
5 and 10 years.
The relative survival (per cent) in different age groups is
listed in Figures 2 and 3. For both histological types there
was a clear decrease in survival with increasing age. Females
under 35 years had a nearly 100% relative survival after
both 5 and 10 years, compared with about 40% 5-year
survival for females above 75 years with follicular and 54%
with papillary tumours. In addition, the difference between
5- and 10-year survival probably increases with age up to 75
years, especially among males. Among the oldest patients
(above 75 years), the difference between 5- and 10-year
relative survival with papillary carcinoma was decreasing
among females, and for follicular tumours the 10-year
relative survival even exceeded that after 5 years, for both
sexes. However, the numbers are small. In summary so far,
age and stage seem to be important prognostic factors, while
sex and histological type seem to be of less importance.
Multivariate analysis of 5-year relative survival
Table IV summarises the multivariate analysis of patients
below 75 years, including sex, age, stage and histology. The
findings contrast to the results from the univariate analysis,
where females have the highest survival. The differences
were, however, rather small. Follicular tumours tend to have
a somewhat worse prognosis than the papillary type. Table
V shows that age (P<0.005) and stage (P<0.001) had a
significant influence on relative survival, while the influence
of sex and histology did not reach a level of significance.
Table I Distribution of cases with respect to sex, tumour stage and histological type (n = 1,055)
Stage I Stage 2 Stage 3 Unknown Total
Histology M F M F M F M F M F
Papillary 90 351 107 190 11 32 2 17 210 590
Follicular 27 156 7 36 8 21 0 0 42 213
Total 117 507 114 226 19 53 2 17 252 803
Table II Distribution of cases with respect to sex, age and histological type (n= 1,055)
0-34 35-54 55-74 75+ Total
Histology M F M F M F M F M F
Papillary 41 146 49 211 99 190 21 43 210 590
Follicular 6 32 9 74 20 81 7 26 42 213
Total 47 178 58 285 119 271 28 69 252 803
Table III Relative 5- and 10-year survival with respect to sex, tumour
logical type
stage and histo-
Stage I Stage 2 Stage 3 Total
Histology M F M F M F M F
Papillary
5 92.7 98.3 86.8 91.7 58.0 46.3 88.2 93.5
10 88.4 97.5 86.2 89.4 15.2 33.9 84.3 92.2
Follicular
5 94.4 96.9 86.8 74.0 34.0 31.7 83.0 87.9
10 93.5 96.9 87.1 78.9 0 22.0 77.8 89.0DIFFERENTIATED THYROID CANCER 233
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Figure 1 Proportion (%) of patients with localised tumours
(stage 1) below and above 55 years and specified for sex and
histological type.
Table IV Multivariate analysis of 5-year relative survival
giving the estimates of effect when sex, age, tumour stage and
histological type have been entered into a GLIM model
Variable Estimate of effect Standard error
Sex
Males
Females 0.15 0.38
Age
0-34
35-54 0.78 0.74
55-74 1.89 0.67
Stage
1
2 2.93 1.32
3 . 4.56 1.31
Histology
Papillary
Follicular 0.61 0.35
Values must be read relative to reference categories of each
variable (a positive value indicates a reduced survival).
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Figure 2 Relative 5- and 10-year survival
specified for age and histological type.
(%) for females
Table V Evaluation of different GLIM models for fitting predicted
values with observed survival, giving the actual difference (deviance,
G2) and degrees of freedom together with the differences between
various models
Explaining Difference Difference
model Deviance in deviance df. df
H+S+A+TS 26.91 25
S+A+TS +2.91 +1
H +A+TS +0.18 +1
H+S +TS + 13.46a +2
H+S+A +67.78b +2
A+TS +3.05 +2
H, histology; S, sex; A, age; TS, tumour stage; d.f., degrees of
freedom. ap<0.005; bp<0.O1.
Table VI Predicted values of 5-year relative survival calculated
from the resultant GLIM model incorporating age and tumour stage
Predicted relative survival
Age Stage I Stage 2 Stage 3
0-34 years 99.8 97.6 86.3
35-54 years 99.5 94.7 72.0
55-74 years 98.5 84.3 35.7
120
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Figure 3 Relative 5- and 10-year survival (%) for males speci-
fied for age and histological type.
The explaining models were not significantly improved when
interaction variables were added (results not shown). The
resultant GLIM model thus incorporates only age and stage,
and predicted values of 5-year relative survival based on this
model are shown in Table VI. It was found that the
prognosis is excellent in stage 1 tumours and that survival
reaches about 85-100% in all groups except patients older
than 35 years with stage 3 tumours.
With the above results in mind the non-parametric rela-
tion between age and stage is given in Figure 4. The
observed relative survival for both sexes and histological
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Figure 4 The 5-year observed relative survival in different stages
and age groups.
types are grouped together in the three different stages. Stage
3 tumours have decreasing survival from a very young age.
The decline for stages I and 2 appears after ages 75 and 55
years respectively.
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Discussion
Our present study includes all verified cases of differentiated
thyroid cancer occurring in Norway during the period 1970-
79. The registration of clinical data and pathology reports in
the Cancer Registry are known to be almost complete.
Selection of patients by mode and place of treatment has
been a serious problem in most other series. Cases have been
collected from different hospitals over long periods of time
to obtain appropriate numbers for statistical analysis. This is
partly avoided in the present material, gathered from a
defined population over a short period of time. Unfortun-
ately the coding of regional lymph node involvement and
extrathyroidal extension to the soft tissue has not been
consistent or uniform in the period 1970-79. This is the main
reason why stage 2 includes both, which could give a rather
unhomogeneous patient population in stage 2.
The single factor analysis showed an excellent prognosis of
localised tumours after both 5 and 10 years of observation,
independent of histological type. The importance of studying
the relative survival, thereby obtaining an adjustment for
unrelated deaths, is also stressed by this finding. Detailed
data on the time and type of tumour recurrences, distant
metastases and causes of death would be of great interest.
There were almost no changes in relative survival between
5 and 10 years in stage 1 and 2 tumours. This is somewhat
unexpected in view of earlier data (Mazzaferri, 1987) but
may be explained by deaths from other causes. It is, however,
well known that even well differentiated thyroid cancer may
develop metastases up to 15-20 years after first treatment.
There are to our knowledge no data indicating an increase in
excess deaths with time. When distant metastases are
present, the prognosis is poorer, especially among females
and in follicular carcinomas. Mortality is furthermore
increased between 5 and 10 years after diagnosis, and this
was most marked among males.
On the basis of univariate analysis of relative survival,
both age and tumour stage had great impact on survival,
while sex and histology showed minor variations. Age and
stage were the only factors of prognostic importance
obtained by the multivariate analysis. Additionally, these
two factors were also interrelated. Localised disease presents
in the younger patients. Several authors have confirmed the
importance of stage (Hannequin et al., 1986; Tubiana et al.,
1985; Simpson et al., 1987). One of the advantages of the
GLIM package is that it can handle large sets of data with
rather small numbers in specific subgroups. We are aware
that some of our subgroups (follicular carcinomas in males)
fit this category.
It has, however, been debated whether lymph node
involvement is of prognostic value. Joensuu et al. (1986)
found that there was no significant difference in corrected
survival between patients with nodal metastases at surgery
and those without. Their material is, however, rather small
with a total of only 200 patients distributed in three
histological types. On the other hand, they claimed that
invasion through the capsule was of significant value. Other
studies support this, concluding that lymph node involve-
ment is important for local recurrence but not for survival
(Tubiana et al., 1985; Hannequin et al., 1986; Simpson et al.,
1987). Patients with regional lymph node involvement and
extrathyroidal invasion were not analysed separately because
of limited data. We have had a preliminary look at our
registrated thyroid cancer occurring after 1980, and these
data seem to indicate that soft tissue involvement of the neck
carries a worse prognosis than nodal metastases.
Our results in the present paper also indicate no difference
between stages I and 2 below 55 years of age, while those
above 55 years had a slightly increased mortality. Finally,
stage 3 patients had a clearly increased mortality among all
age groups.
There seems to be full agreement among all authors that
age is a major prognostic factor (Tubiana et al., 1985;
Simpson et al., 1987). It is more uncertain at which age the
mortality risk increases. Some authors have observed a
decline in relative survival after the age of 40 years (Cady et
al., 1985), while Tubiana et al. (1985) found this decline
appearing some years later. The multifactorial analysis in the
present investigation confirms age as a valuable prognostic
factor and indicates that the major decline in relative
survival appears after the age of 55 years, This is in keeping
with Simpson et al. (1987), who found more aggressive
behaviour in patients beyond the age of 60. The discrepan-
cies may partly be due to different groupings of age.
Additionally, differences in stage distribution and histo-
logical type may also contribute to such conflicting results.
We have shown the impact of age on survival to be clearly
dependent on stage, and this may also indicate biological
differences between tumours presenting in various stages.
The multivariate analysis excludes patients over 75 years.
This is done mainly because it is often a problem to give the
correct expected survival in older age.
The histopathological typing in this study was based on
the WHO classification from 1974 (Hedinger & Sobin, 1974).
The slides have not been reviewed, but all reports were
examined to adjust the coding. Mixed tumours with both
papillary and follicular elements were classified as papillary
carcinomas. As stated by Simpson et al. (1987), the distinc-
tion between papillary and follicular thyroid cancer may be
of little more than academic interest. The follicular group
was not subdivided with respect to differentiation grade.
This may be an explanation of the lack of significant
difference in survival between the two histological types.
Tubiana et al. (1985) found no difference between papillary
and well differentiated follicular carcinomas, while follicular
tumours of lower differentiation had a worse prognosis. This
is confirmed in the EORTC study (Byar et al., 1979) and by
Hannequin et al. (1986). In view of earlier reports (Saxen et
al., 1978), some follicular adenomas may also have been
included, but these would only mask a difference of survival
in stage 1 tumours. Additionally some papillary carcinomas
may be incorrectly diagnosed as follicular carcinomas.
Sex as prognostic factor is also debated, although some
studies claim that females have a better final outcome than
males (Simpson & McKinney, 1985). We cannot confirm this
finding. In our study, which included 803 females and 252
males, no sex differences persist after the multivariate analy-
sis of patients below 75 years of age. This is partly con-
firmed in a paper by Simpson et al. (1987).
One practical conclusion on the discrepancy between
different prognostic studies could be that the prognostic
factors may change from one population to another
(Hannequin et al., 1986). Thus one should be cautious in
applying one set of prognostic factors to other populations.
On the other hand, there seems to be full agreement that age
and stage are independent and important prognostic factors.
Studies on cellular DNA content have shown an increasing
aneuploidy with age in both benign and malignant thyroid
tumours (Joensuu et al., 1986). This may be one explanation
of the great prognostic importance of age. It therefore seems
to be a clear biological difference between subgroups
of thyroid -carcinomas. Further studies- on cause-specific
mortality and tumour recurrences as well as extensive
morphological studies are now in progress in Norway.
The Norwegian Thyroid Cancer Project wish to thank The
Norwegian Cancer Society for grants and financial support.
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